This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Logo

Azelaic Acid 20% vs Hydroquinone 4% in Epidermal Melasma

Sponsored by Gujranwala medical college District Headquarters Hospital, Gujranwala

About this trial

Last updated 5 months ago

Study ID

IRB.23/GMC

Status

Completed

Type

Interventional

Phase

N/A

Placebo

No

Accepting

All Ages
All Sexes

Trial Timing

Ended 7 months ago

What is this trial about?

Melasma is a common skin condition that causes dark patches on the face and can significantly affect quality of life. This study compared two commonly used topical treatments, 20% azelaic acid and 4% hydroquinone, in adults with epidermal melasma. Participants with epidermal melasma were randomly assigned to receive either azelaic acid 20% or hydroquinone 4% for a period of 12 weeks. The severity of melasma was assessed at baseline and monthly using the Melasma Area and Severity Index (MASI) score. Side effects such as irritation, redness, burning, itching, and dryness were also monitored throughout the study. The purpose of this study was to compare the effectiveness and safety of azelaic acid and hydroquinone in reducing melasma severity and to determine whether azelaic acid can be used as a safe alternative to hydroquinone.

What are the participation requirements?

Inclusion Criteria

* Patients with clinically diagnosed epidermal melasma confirmed by Wood's lamp examination * Male or female participants of any age * Willingness to provide written informed consent * Ability to comply with study procedures and follow-up visits Exclusion Criteria:- Dermal or mixed-type melasma * Active cutaneous or facial skin infection * History of keloid formation * Recent use of other topical or systemic depigmenting agents * Presence of photosensitive disorders * Pregnancy or lactation * Refusal or inability to provide written informed consent

Exclusion Criteria